Team RxPinoy's List: Health Care and the Internet

"If anyone was confused about whether the FDA might regulate pharma company marketing on Facebook and other social media channels, Novartis has unintentionally helped clear the air.\n\nNovartis recently received a warning letter from the FDA for using a Facebook widget that provided users with information about Tasigna, which is indicated for Ph+ chronic myeloid leukemia, but failed to also provide the FDA-required risk and safety information. Novartis has since removed the widget, and although there still exists quite a bit of uncertainty surrounding FDA regulation of social media marketing activity (at least until the final rules are published), the pharma industry can now be certain that omitting risk information in the name of Internet-style brevity is asking for enforcement action."